These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 1541530)

  • 21. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
    Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
    J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
    Cherry JD; Gornbein J; Heininger U; Stehr K
    Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.
    Seubert A; D'Oro U; Scarselli M; Pizza M
    Expert Rev Vaccines; 2014 Oct; 13(10):1191-204. PubMed ID: 25183193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.
    Lima FA; Miyaji EN; Quintilio W; Raw I; Ho PL; Oliveira ML
    Vaccine; 2013 May; 31(20):2465-70. PubMed ID: 23541622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates.
    Gzyl A; Augustynowicz E; Gniadek G; Rabczenko D; Dulny G; Slusarczyk J
    Vaccine; 2004 Jun; 22(17-18):2122-8. PubMed ID: 15149768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
    Boros CA; Hanlon M; Gold MS; Roberton DM
    Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment.
    Nencioni L; Volpini G; Peppoloni S; Bugnoli M; De Magistris T; Marsili I; Rappuoli R
    Infect Immun; 1991 Feb; 59(2):625-30. PubMed ID: 1702767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
    Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
    J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune responses to pertussis vaccines concurrently administered with viral vaccines.
    Halperin SA; Eastwood BJ; Langley JM
    Ann N Y Acad Sci; 1995 May; 754():89-96. PubMed ID: 7625684
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.
    Roduit C; Bozzotti P; Mielcarek N; Lambert PH; del Giudice G; Locht C; Siegrist CA
    Infect Immun; 2002 Jul; 70(7):3521-8. PubMed ID: 12065491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin.
    Kimura M; Kuno-Sakai H; Kamiya H; Ueda K; Isomura S; Koike M; Kato T; Ozaki T; Hirose M; Egami T
    Acta Paediatr Jpn; 1995 Oct; 37(5):562-74. PubMed ID: 8533580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
    Stenger RM; Smits M; Kuipers B; van Gaans-van den Brink J; Poelen M; Boog CJ; van Els CA
    Vaccine; 2010 Sep; 28(40):6637-46. PubMed ID: 20637762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus.
    van Gageldonk PG; van Schaijk FG; van der Klis FR; Berbers GA
    J Immunol Methods; 2008 Jun; 335(1-2):79-89. PubMed ID: 18407287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge.
    Nascimento IP; Dias WO; Quintilio W; Christ AP; Moraes JF; Vancetto MD; Ribeiro-Dos-Santos G; Raw I; Leite LC
    Microbes Infect; 2008 Feb; 10(2):198-202. PubMed ID: 18248757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
    Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
    Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.